[go: up one dir, main page]

KR970700646A - Benzylamine Derivatives Including Nitrooxy Groups, And Their Uses For The Treatment Of Cardiovascular Diseases And Intraocular Pressure Elevation - Google Patents

Benzylamine Derivatives Including Nitrooxy Groups, And Their Uses For The Treatment Of Cardiovascular Diseases And Intraocular Pressure Elevation Download PDF

Info

Publication number
KR970700646A
KR970700646A KR1019960703871A KR19960703871A KR970700646A KR 970700646 A KR970700646 A KR 970700646A KR 1019960703871 A KR1019960703871 A KR 1019960703871A KR 19960703871 A KR19960703871 A KR 19960703871A KR 970700646 A KR970700646 A KR 970700646A
Authority
KR
South Korea
Prior art keywords
substituted
alkyl
group
phenyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019960703871A
Other languages
Korean (ko)
Inventor
브론 얀
얀 슈테르크 게르트
팀머만 헨드리크
이. 제이. 페어만 메타
페체 판 데어 베르프 얀
Original Assignee
헤르베르트 루프·울리히 볼프
빅 네덜란드 비브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헤르베르트 루프·울리히 볼프, 빅 네덜란드 비브이 filed Critical 헤르베르트 루프·울리히 볼프
Publication of KR970700646A publication Critical patent/KR970700646A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
    • C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은 하기 일반식(Ⅰ)의 화합물 및 이의 염에 관한 것이다.The present invention relates to compounds of the general formula (I) and salts thereof.

[화학식 7][Formula 7]

상기식중, A1은 C1-15의 알킬렌, C5-7의시클로알킬렌 또는 디-C1-4의 알킬렌-C5-7의 시클로알칸이고; R1은 수소, C1-7의 알킬 또는 C3-8의 시클로알킬이며; R2는 수소, C1-7의 알킬, C3-8의 시클로알킬 또는 A2-Y이거나, 또는 R1 및 R2는 서로 질소원자와 함께 결합하여 피롤리딘, 피페라딘, 피페라진, 모폴린 및 호모피페라진으로 구성된 군중에서 선택된 비치환된 또는 치환된 5-, 6- 또는 7-고리의 헤테로사이클을 형성하고; A2는 C1-15의 알킬렌, C5-7의 시클로알킬렌 또는 디-C1-4의 알킬렌-C5-7의 시클로알칸이고; Y는 R3, NH2, NH-R4 또는 S-R5로는, -치환된 피콜리딘기는 C1-4의 알킬, C1-4의 알콕시 및 히드록시로 구성된 군중에서 선택된 하나 또는 2개의 동일하거나 다른 치환기로 치환되고, -치환된 피페리딘기는 C1-4의 알킬, C1-4의 알콕시 및 히드록시로 구성된 군중에서 선택된 하나 또는 그 이상의 동일하거나 다른 치환기로 치환되고, -치환된 피페라진기는 C1-4의 알킬기가 2-, 3-, 5- 또는 6-위치에 치환될 수 있고, 4 위치에는 C1-4의 알킬, C1-4의 알콕시카르보닐, C1-4의 알킬카르보닐, R6, R7 및 R8로 치환된 페닐, 페닐기에 R6, R7 및 R8가 치환된 페닐-C1-4-알킬, 페닐기에 R6, R7 및 R8가 치환된 벤조일, 피콜리노일, 니코티노일, 이소니코티노일, 임의로 할로겐 또는 C1-4-알킬 치환된 벤즈히드릴 및 R4기로 구성된 군중에서 선택된 치환기로 치환되며, -치환된 모폴린기는 하나 또는 2개의 동일하거나 다른 C1-4의 알킬기로 치환되며, -치환된 호모피페라진기는 4위치에는 C1-4-알킬, C1-4-알콕시카르보닐, C1-4-알킬카르보닐, R6, R7 및 R8로 치환된 페닐, 페닐기에 R6, R7 및 R8가 치환된 페닐-C1-4-알킬 및 페닐기에 R6, R7 및 R8가 치환된 벤조일로 구성된 군중에서 선택된 치환기로 치환되고; R3은 푸릴, 나프틸, 테트라히드로나프틸, -O-Al-ONO2치환된 페닐 또는 R6, R7 및 R8로 치환된 페닐이며; R4는 C1-7-알킬 또는 치환된 -CH2-CH(OH)-(CH2O)p-Ar이며; R5는 R6, R7 및 R8 치환된 페닐, R6, R7 및 R8 치환된 페닐-C1-4-알킬, 임의로 할로겐 또는 C1-4-알킬 치환된 벤즈히드릴, 디벤조-C5-7-시클로알카닐, 디벤조시클로헵테닐 또는 벤조-피리도-C5-7-시클로알카닐이고; R6은 수소, C1-4-알킬, C1-4-알콕시, C1-4-알콕시, C1-4-알킬카르보닐, 할로겐 아미노, 모노- 또는 디-(C1-4알킬)아미노 또는 니트로이고; R7은 수소, C1-4-알킬, C1-4-알콕시, 할로겐 또는 니트로이고; R8은 수소 또는 트리플루오로메틸이고; P는 0 또는 1의 정수이며; Ar은 완전 또는 부분 불포화된 모노시클릭(5 내지 6의 고리원자 포함) 또는 비시클릭(9 내지 10개의 고리원자 포함)의 탄화수소 고리 시스템으로서, 이때 1,2 또는 3의 탄소원자에는 질소(N), 산소(O) 또는 황(S)중에서 선택된 헤테로원자가 삽입될 수 있고, 또한 C1-4-알킬, C1-4-알콕시, C1-4-알킬티오, C1-4알콕시-C1-4-알킬,C1-4-알콕시-C1-4-알콕시, C3-4-알케닐, C3-4-알케닐옥시, C3-8-시클로알킬, C5-10-시클로알킬알콕시알킬, C1-4-알킬카르보닐, C1-4-알킬카르보닐아미노, 카르바모일, 카르바모일-C1-4-알킬, 할로겐, 히드록시, 옥소 니트로, 시안 C1-4-알킬설폰아미도, 아미노, 모노- 또는 디-(C1-4-알킬)아미노, 우레이도, 모노- 또는 디-(C1-4-알킬)우레이도, 모노-또는 디-(C3-8-시클로알킬)우레이도, 트리플루오로메틸, 완전 또는 부분적으로 플루오로 치환된 C1-4-알콕시, C1-4-알콕시카르보닐, 테트라히드로푸르푸릴옥시 또는 모폴리노로 구성된 군중에서 선택된 하나 또는 2개의 동일하거나 또는 다른 치환기로 치환될 수 있다. 이들 화합물은 심장 혈관 질환 및 안압 상승의 치료에 유용한다. Wherein A 1 is C 1-15 alkylene, C 5-7 cycloalkylene or di-C 1-4 alkylene-C 5-7 cycloalkane; R 1 is hydrogen, C 1-7 alkyl or C 3-8 cycloalkyl; R 2 is hydrogen, C 1-7 alkyl, C 3-8 cycloalkyl or A 2 -Y, or R 1 and R 2 are bonded together with a nitrogen atom to each other to form pyrrolidine, piperadine, piperazine, morpholine and To form an unsubstituted or substituted 5-, 6- or 7-ring heterocycle selected from the group consisting of homopiperazine; A 2 is C 1-15 alkylene, C 5-7 cycloalkylene or di-C 1-4 alkylene-C 5-7 cycloalkane; Y is R3, NH 2, NH-R4-R5 or S roneun,-substituted P-collidine group is one selected from the group consisting of alkoxy and hydroxy alkyl, C 1-4 of C 1-4, or two the same or replaced by another substituent group, - substituted piperidine group is substituted by one or more identical or different substituents selected from the group consisting of alkoxy and hydroxy alkyl, C 1-4 of C 1-4, - substituted piperazine The radical group may be substituted with an alkyl group of C 1-4 in 2-, 3-, 5- or 6-position, and in position 4 an alkyl of C 1-4 , alkoxycarbonyl of C 1-4 , C 1-4 Alkylcarbonyl, phenyl substituted with R6, R7 and R8, phenyl-C 1-4 -alkyl substituted with R6, R7 and R8 in the phenyl group, benzoyl, picolinoyl substituted with R6, R7 and R8 in the phenyl group, nicotinoyl, isonicotinoyl, optionally halogen or C 1-4 - alkyl is substituted with a substituted benzhydryl group and R4 substituents selected from the group consisting of, di-substituted morpholine Is one or two the same or different, and substituted with an alkyl group of C 1-4, - substituted No. fur Blow oscillator is the 4-position is C 1-4 - alkyl, C 1-4 - alkoxycarbonyl, C 1-4 - A substituent selected from the group consisting of alkylcarbonyl, phenyl substituted with R6, R7 and R8, phenyl-C 1-4 -alkyl substituted with R6, R7 and R8 in the phenyl group and benzoyl substituted with R6, R7 and R8 in the phenyl group Substituted with; R3 is furyl, naphthyl, tetrahydronaphthyl, -O-Al-ONO 2 substituted phenyl or phenyl substituted with R6, R7 and R8; R 4 is C 1-7 -alkyl or substituted —CH 2 —CH (OH) — (CH 2 O) p -Ar; R5 is R6, R7 and R8 substituted phenyl, R6, R7 and R8 substituted phenyl-C 1-4 -alkyl, optionally halogen or C 1-4 -alkyl substituted benzhydryl, dibenzo-C 5-7- Cycloalkanyl, dibenzocycloheptenyl or benzo-pyrido-C 5-7 -cycloalkanyl; R6 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxy, C 1-4 -alkylcarbonyl, halogen amino, mono- or di- (C 1-4 alkyl) amino Or nitro; R 7 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, halogen or nitro; R8 is hydrogen or trifluoromethyl; P is an integer of 0 or 1; Ar is a hydrocarbon ring system of fully or partially unsaturated monocyclic (including 5 to 6 ring atoms) or bicyclic (including 9 to 10 ring atoms), wherein nitrogen at 1, 2 or 3 carbon atoms (N Heteroatoms selected from oxygen, (O) or sulfur (S) can be inserted, and also C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkylthio, C 1-4 alkoxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkoxy, C 3-4 -alkenyl, C 3-4 -alkenyloxy, C 3-8 -cycloalkyl, C 5-10- Cycloalkylalkoxyalkyl, C 1-4 -alkylcarbonyl, C 1-4 -alkylcarbonylamino, carbamoyl, carbamoyl-C 1-4 -alkyl, halogen, hydroxy, oxo nitro, cyan C 1 -4 -alkylsulfonamido, amino, mono- or di- (C 1-4 -alkyl) amino, ureido, mono- or di- (C 1-4 -alkyl) ureido, mono- or di- ( C 3-8 - cycloalkyl) ureido values in Fig, methyl, fully or in part, a fluoroalkyl trifluoroacetate A C 1-4 - alkoxy, C 1-4 - may be substituted with alkoxycarbonyl, tetrahydrofurfuryl-oxy or morpholinyl furnace one or two same or different substituents selected from the consisting of a crowd. These compounds are useful for the treatment of cardiovascular disease and elevated intraocular pressure.

Description

니트록시기를 포함한 벤질아민 유도체, 및 심장 혈관 질환과 안압 상승의 치료를 위한 이의 용도(NITROXY GROUP-CONTAINING BENZYLAMINE DERIVATIVES AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES, AS WELL AS INCREASED INTRA-OCULAR PRESSURE)Benzylamine Derivatives Including Nitrooxy Groups, And Their Uses For The Treatment Of Cardiovascular Diseases And Intraocular Pressure Elevation

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (8)

하기 일반식(Ⅰ)의 화합물 및 이의 염:A compound of formula (I) and salts thereof: [화학식 4][Formula 4] 상기식중, A1은 C1-15의 알킬렌, C5-7의시클로알킬렌 또는 디-C1-4의 알킬렌-C5-7의 시클로알칸이고; R1은 수소, C1-7의 알킬 또는 C3-8의 시클로알킬이며; R2는 수소, C1-7의 알킬, C3-8의 시클로알킬 또는 A2-Y이거나, 또는 R1 및 R2는 서로 질소원자와 함께 결합하여 피롤리딘, 피페라딘, 피페라진, 모폴린 및 호모피페라진으로 구성된 군중에서 선택된 비치환된 또는 치환된 5-, 6- 또는 7-고리의 헤테로사이클을 형성하고; A2는 C1-15의 알킬렌, C5-7의 시클로알킬렌 또는 디-C1-4의 알킬렌-C5-7의 시클로알칸이고; Y는 R3, NH2, NH-R4 또는 S-R5로는, -치환된 피를리딘기는 C1-4의 알킬, C1-4의 알콕시 및 히드록시로 구성된 군중에서 선택된 하나 또는 2개의 동일하거나 다른 치환기로 치환되고, -치환된 피페리딘기는 C1-4의 알킬, C1-4의 알콕시 및 히드록시로 구성된 군중에서 선택된 하나 또는 그 이상의 동일하거나 다른 치환기로 치환되고, -치환된 피페라진기는 C1-4의 알킬기가 2-, 3-, 5- 또는 6-위치에 치환될 수 있고, 4 위치에는 C1-4의 알킬, C1-4의 알콕시카르보닐, C1-4의 알킬카르보닐, R6, R7 및 R8로 치환된 페닐, 페닐기에 R6, R7 및 R8가 치환된 페닐-C1-4-알킬 페닐기에 R6, R7 및 R8가 치환된 벤조일, 피콜리노일, 니코티노일, 이소니코티노일, 임의로 할로겐 또는 C1-4-알킬 치환된 벤즈히드릴 및 R4기로 구성된 군중에서 선택된 치환기로 치환되며, -치환된 모폴린기는 하나 또는 2개의 동일하거나 다른 C1-4의 알킬기로 치환되며, -치환된 호모피페라진기는 4위치에는 C1-4-알킬, C1-4-알콕시카르보닐, C1-4-알킬카르보닐, R6, R7 및 R8로 치환된 페닐, 페닐기에 R6, R7 및 R8가 치환된 페닐-C1-4-알킬 및 페닐기에 R6, R7 및 R8가 치환된 벤조일로 구성된 군중에서 선택된 치환기로 치환되고; R3은 푸릴, 나프틸, 테트라히드로나프틸, -O-Al-ONO2치환된 페닐 또는 R6, R7 및 R8로 치환된 페닐이며; R4는 C1-7-알킬 또는 치환된 -CH2-CH(OH)-(CH2O)p-Ar이며; R5는 R6, R7 및 R8 치환된 페닐, R6, R7 및 R8 치환된 페닐-C1-4-알킬, 임의로 할로겐 또는 C1-4-알킬 치환된 벤즈히드릴, 디벤조-C5-7-시클로알카닐, 디벤조시클로헵테닐 또는 벤조-피리도-C5-7-시클로알카닐이고; R6은 수소, C1-4-알킬, C1-4-알콕시, C1-4-알콕시, C1-4-알킬카르보닐, 할로겐 아미노, 모노- 또는 디-(C1-4알킬)아미노 또는 니트로이고; R7은 수소, C1-4-알킬, C1-4-알콕시, 할로겐 또는 니트로이고; R8은 수소 또는 트리플루오로메틸이고; P는 0 또는 1의 정수이며; Ar은 완전 또는 부분 불포화된 모노시클릭(5 내지 6의 고리원자 포함) 또는 비시클릭(9 내지 10개의 고리원자 포함)의 탄화수소 고리 시스템으로서, 이때 1,2 또는 3의 탄소원자에는 질소(N), 산소(O) 또는 황(S)중에서 선택된 헤테로원자가 삽입될 수 있고, 또한 C1-4-알킬, C1-4-알콕시, C1-4-알킬티오, C1-4알콕시-C1-4-알킬,C1-4-알콕시-C1-4-알콕시, C3-4-알케닐, C3-4-알케닐옥시, C3-8-시클로알킬, C5-10-시클로알킬알콕시알킬, C1-4-알킬카르보닐, C1-4-알킬카르보닐아미노, 카르바모일, 카르바모일-C1-4-알킬, 할로겐, 히드록시, 옥소, 니트로, 시안, C1-4-알킬설폰아미도, 아미노, 모노- 또는 디-(C1-4-알킬)아미노, 우레이도, 모노- 또는 디-(C1-4-알킬)우레이도, 모노-또는 디-(C3-8-시클로알킬)우레이도, 트리플루오로메틸, 완전 또는 부분적으로 플루오로 치환된 C1-4-알콕시, C1-4-알콕시카르보닐, 테트라히드로푸르푸릴옥시 또는 모폴리노로 구성된 군중에서 선택된 하나 또는 2개의 동일하거나 또는 다른 치환기로 치환될 수 있다. Wherein A 1 is C 1-15 alkylene, C 5-7 cycloalkylene or di-C 1-4 alkylene-C 5-7 cycloalkane; R 1 is hydrogen, C 1-7 alkyl or C 3-8 cycloalkyl; R 2 is hydrogen, C 1-7 alkyl, C 3-8 cycloalkyl or A 2 -Y, or R 1 and R 2 are bonded together with a nitrogen atom to each other to form pyrrolidine, piperadine, piperazine, morpholine and To form an unsubstituted or substituted 5-, 6- or 7-ring heterocycle selected from the group consisting of homopiperazine; A 2 is C 1-15 alkylene, C 5-7 cycloalkylene or di-C 1-4 alkylene-C 5-7 cycloalkane; Y is R3, NH 2, NH-R4-R5 or S roneun, - or one or two same selected from the group consisting of alkyl, alkoxy and hydroxy on the C 1-4 C 1-4 group is optionally substituted naphthyridine the blood replaced by another substituent group, - substituted piperidine group is substituted by one or more identical or different substituents selected from the group consisting of alkoxy and hydroxy alkyl, C 1-4 of C 1-4, - substituted piperazine The radical group may be substituted with an alkyl group of C 1-4 in 2-, 3-, 5- or 6-position, and in position 4 an alkyl of C 1-4 , alkoxycarbonyl of C 1-4 , C 1-4 Alkylcarbonyl, phenyl substituted by R6, R7 and R8, phenyl substituted by R6, R7 and R8 in the phenyl group, benzoyl, picolinoyl, nicotine substituted by R6, R7 and R8 in the phenyl-C 1-4 -alkyl phenyl group Tino days, isonicotinoyl, optionally halogen or C 1-4 - alkyl is substituted with a substituted benzhydryl group and R4 substituents selected from the group consisting of, di-substituted morpholine Is one or two the same or different, and substituted with an alkyl group of C 1-4, - substituted No. fur Blow oscillator is the 4-position is C 1-4 - alkyl, C 1-4 - alkoxycarbonyl, C 1-4 - A substituent selected from the group consisting of alkylcarbonyl, phenyl substituted with R6, R7 and R8, phenyl-C 1-4 -alkyl substituted with R6, R7 and R8 in the phenyl group and benzoyl substituted with R6, R7 and R8 in the phenyl group Substituted with; R3 is furyl, naphthyl, tetrahydronaphthyl, -O-Al-ONO 2 substituted phenyl or phenyl substituted with R6, R7 and R8; R 4 is C 1-7 -alkyl or substituted —CH 2 —CH (OH) — (CH 2 O) p -Ar; R5 is R6, R7 and R8 substituted phenyl, R6, R7 and R8 substituted phenyl-C 1-4 -alkyl, optionally halogen or C 1-4 -alkyl substituted benzhydryl, dibenzo-C 5-7- Cycloalkanyl, dibenzocycloheptenyl or benzo-pyrido-C 5-7 -cycloalkanyl; R6 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkoxy, C 1-4 -alkylcarbonyl, halogen amino, mono- or di- (C 1-4 alkyl) amino Or nitro; R 7 is hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, halogen or nitro; R8 is hydrogen or trifluoromethyl; P is an integer of 0 or 1; Ar is a hydrocarbon ring system of fully or partially unsaturated monocyclic (including 5 to 6 ring atoms) or bicyclic (including 9 to 10 ring atoms), wherein nitrogen at 1, 2 or 3 carbon atoms (N Heteroatoms selected from oxygen, (O) or sulfur (S) can be inserted, and also C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -alkylthio, C 1-4 alkoxy-C 1-4 -alkyl, C 1-4 -alkoxy-C 1-4 -alkoxy, C 3-4 -alkenyl, C 3-4 -alkenyloxy, C 3-8 -cycloalkyl, C 5-10- Cycloalkylalkoxyalkyl, C 1-4 -alkylcarbonyl, C 1-4 -alkylcarbonylamino, carbamoyl, carbamoyl-C 1-4 -alkyl, halogen, hydroxy, oxo, nitro, cyan, C 1-4 -alkylsulfonamido, amino, mono- or di- (C 1-4 -alkyl) amino, ureido, mono- or di- (C 1-4 -alkyl) ureido, mono- or di - to - (C 3-8 cycloalkyl) ureido, trifluoromethyl fluoro methyl, fully or partially Hwandoen C 1-4 - alkoxy, C 1-4 - may be substituted with alkoxycarbonyl, tetrahydrofurfuryl-oxy or morpholinyl furnace one or two same or different substituents selected from the consisting of a crowd. 제1항에 있어서, Al이 C2-10의 알킬 또는 디메틸시클로헥산이고, R1이 수소이며, R2가 수소 또는 A2-Y이거나, 또는 R1 및 R2가 서로 질소원자와 함께 결합하여 하나의 비치환된 또는 치환된 피페라진기를 형성하고, A2는 C1-10의 알킬렌이고, Y는 R3, NH2, NH-R4 또는 S-R5이고, - 치환된 피페라진기는 C1-4의 알콕시카르보닐, C1-4의 알킬카르보닐, 피콜리노일, 니코티노일, 이소니코티노일, 벤즈히드릴 및 R4로 구성된 군중에서 선택된 치환기로 4-위치가 치환되고, R3는 페닐 또는 -O-Al-ONO2로 치환된 페닐이고, R4는 치환된 -CH2-CH(OH)-(CH2O)p-Ar이며, R5는 임의로 할로겐 또는 C1-4의 알킬로 치환된 벤즈히드릴, 디벤조시클로헵타닐, 디벤조시클로헵테닐 또는 벤조-피리도-시클로헵타닐이고, p는 정수 1이며, Ar은 페닐, 4-(2-메톡시에톡시)-페닐, 2-알릴페닐, 2-클로로-5-메틸페닐, 2-알릴옥시페닐, 2-시클로펜틸페닐, 2-시아노페닐 또는 1-나프틸인 상기 일반식(Ⅰ)의 화합물 및 이의 염.The compound of claim 1, wherein Al is C 2-10 alkyl or dimethylcyclohexane, R 1 is hydrogen, R 2 is hydrogen or A 2 -Y, or R 1 and R 2 are bonded together with a nitrogen atom to form one unsubstituted compound. Form a substituted or substituted piperazine group, A 2 is C 1-10 alkylene, Y is R 3, NH 2 , NH-R 4 or S-R 5, and the substituted piperazine group is C 1-4 alkoxycarb 4-position is substituted with a substituent selected from the group consisting of carbonyl, C 1-4 alkylcarbonyl, picolinoyl, nicotinoyl, isnicotinoyl, benzhydryl and R 4, and R 3 is phenyl or -O- Phenyl substituted with Al-ONO 2 , R 4 is substituted -CH 2 -CH (OH)-(CH 2 O) p-Ar, and R 5 is optionally substituted benzhydryl substituted with halogen or C 1-4 alkyl; , Dibenzocycloheptanyl, dibenzocycloheptenyl or benzo-pyrido-cycloheptanyl, p is an integer of 1, Ar is phenyl, 4- (2-methoxyethoxy) -phenyl, 2-allylphenyl , 2-chloro-5-meth Phenyl, 2-allyloxy-phenyl, 2-cyclopentyl-phenyl, 2-cyanophenyl or 1-naphthyl A compound and salts thereof of the general formula (Ⅰ). 제1항에 있어서 Al이 C2-20의 알킬 또는 디메틸렌시클로헥산이고, R1이 수소이며, R2가 수소 또는 A2-Y이거나, 또는 R1 및 R2가 서로 질소원자와 함께 결합하여 하나의 비치환된 또는 치환된 피페라진기를 형성하고, A2는 C1-10의 알킬렌이고, Y는 R3, NH2,NH-R4 또는 S-R5이고, -치환된 피페라진기는 C1-4의 알킬카르보닐, 니코티노일, 벤즈히드릴 및 R4로 구성된 군중에서 선택된 치환기가 4-위치가 치환되고, R3는 페닐 또는 -O-Al-ONO2로 치환된 페닐이고 R4는 치환된 -CH2-CH(OH)-(CH2O)p-Ar이며, R5는 C1-4의 알킬로 치환된 베즈히드릴, 벤즈히드릴, 디벤조시클로헵타닐, 디벤조시클로헵테닐 또는 클로로-치환된 벤조-피리도-시클로헵타닐이고, p는 정수 1이며, Ar은 페닐, 2-알릴페닐, 또는 1-나프틸인 상기 일반식(Ⅰ)의 화합물 및 이의 염.The compound of claim 1, wherein Al is C 2-20 alkyl or dimethylenecyclohexane, R 1 is hydrogen, R 2 is hydrogen or A 2 -Y, or R 1 and R 2 are bonded together with a nitrogen atom to form one unsubstituted compound. Form a substituted or substituted piperazine group, A 2 is C 1-10 alkylene, Y is R 3, NH 2 , NH-R 4 or S-R 5, and the -substituted piperazine group is alkyl 1 C 1-4 A substituent selected from the group consisting of carbonyl, nicotinoyl, benzhydryl and R4 is substituted in 4-position, R3 is phenyl substituted with phenyl or -O-Al-ONO 2 and R4 is substituted -CH 2 -CH (OH)-(CH 2 O) p-Ar, R 5 is benzhydryl, benzhydryl, dibenzocycloheptanyl, dibenzocycloheptenyl or chloro-substituted benzo substituted with C 1-4 alkyl -A pyrido-cycloheptanyl, p is an integer of 1, and Ar is phenyl, 2-allylphenyl, or 1-naphthyl, and a salt thereof. 제1항에 있어서, 2-(2-니트록시에톡시)-N-(2-페닐에틸)벤질아민, N-(2-[(4-메틸-알파-페닐벤질)티오]에틸}-4-(2-니트록시에톡시)벤질아민, N-{2-[(5H-디벤즈[a,d]시클로헵텐-5-일)티오]-에틸}-2-(2,2-디메틸-3-니트록시프로폭시)벤질아민, N-[2-(2,2-디메틸-3-니트록시프로픽시)벤질]피페라진, 3-(2-니트록시에톡시)벤질아민, N-아세틸-N′-[2-(2,2-디메틸-3-니트록시프로픽시)벤질]피페라진, 2-(2-니트록시에톡시)벤질아민, N-[2-(2,2-디메틸-3-니트록시프로폭시)벤질]-N′-(3-피리딘카르보닐)피페라진, N-[3-(2-니트록시에톡시)벤질]피페라진, 1-(2-히드록시-3-페녹시프로필)-4-[3-(2-니트록시에틸)벤질]피페라진, 디-{2-[(4-니트록시메틸[트랜스]시클로헥실)메톡시]벤질}아민, N-디페닐메틸-N′-[4-(2-니트록시에톡시)벤질]피페라진, N-(4-2-니트록시에톡시)벤질]호모피페라진, N-[4-(2-니트록시에톡시)벤질]-N′-(2-히드록시-3-페녹시프로필)-1, 6-헥실렌디아민, N-[3-(2-알릴페녹시)-2-히드록시프로필]-N′-[4-(2-니트록시에톡시)벤질-1,8-옥틸렌디아민, N-[3-(2-알릴페녹시)-2-히드록시프로필]-N′-[2-(2-니트록시에톡시)벤질]-1,8-옥틸렌디아민, N-[3-(2-알릴페녹시)-2-히드록시프로필]-N′-[3-(2-니트록시에톡시)벤질-1,8-옥틸렌디아민, N-(2-히드록시-3-나프틸옥시프로필)-N′[4-(2-니트록시에톡시)벤질]-1,4-부틸렌디아민, N-[3-(1-나프틸옥시)-2-히드록시프로필]-N′-[3-(2-니트록시에톡시)벤질-1,4-부틸렌디아민, N-[2-(10-니트록시데실옥시)벤질]-1,6-헥실렌디아민으로 구성된 군중에서 선택된 일반식(Ⅰ)의 화합물 및 이의 염.2. The compound of claim 1, wherein 2- (2-nitoxyethoxy) -N- (2-phenylethyl) benzylamine, N- (2-[(4-methyl-alpha-phenylbenzyl) thio] ethyl} -4 -(2-nitroethoxy) benzylamine, N- {2-[(5H-dibenz [a, d] cyclohepten-5-yl) thio] -ethyl} -2- (2,2-dimethyl- 3-nitropropoxy) benzylamine, N- [2- (2,2-dimethyl-3-nitropropoxy) benzyl] piperazine, 3- (2-nitroethoxy) benzylamine, N-acetyl -N '-[2- (2,2-dimethyl-3-nitoxypropoxy) benzyl] piperazine, 2- (2-nitoxyethoxy) benzylamine, N- [2- (2,2-dimethyl -3-nitropropoxy) benzyl] -N '-(3-pyridinecarbonyl) piperazine, N- [3- (2-nitroethoxy) benzyl] piperazine, 1- (2-hydroxy- 3-phenoxypropyl) -4- [3- (2-nitoxyethyl) benzyl] piperazine, di- {2-[(4-nitromethyl [trans] cyclohexyl) methoxy] benzyl} amine, N -Diphenylmethyl-N '-[4- (2-nitoxyethoxy) benzyl] piperazine, N- (4-2-nitroethoxy) benzyl] hompiperazine, N- [4- (2- Nitrooxyethoxy Benzyl] -N '-(2-hydroxy-3-phenoxypropyl) -1, 6-hexylenediamine, N- [3- (2-allylphenoxy) -2-hydroxypropyl] -N ′-[4- (2-nitroethoxy) benzyl-1,8-octylenediamine, N- [3- (2-allylphenoxy) -2-hydroxypropyl] -N ′-[2- ( 2-nitroethoxy) benzyl] -1,8-octylenediamine, N- [3- (2-allylphenoxy) -2-hydroxypropyl] -N '-[3- (2-nitrohydroxy Methoxy) benzyl-1,8-octylenediamine, N- (2-hydroxy-3-naphthyloxypropyl) -N '[4- (2-nitoxyethoxy) benzyl] -1,4-butylene Diamine, N- [3- (1-naphthyloxy) -2-hydroxypropyl] -N '-[3- (2-nitoxyethoxy) benzyl-1,4-butylenediamine, N- [2 A compound of formula (I) selected from the group consisting of-(10-nitrodecyloxy) benzyl] -1,6-hexylenediamine and salts thereof. 하기 일반식(Ⅱ)의 알데히드를 하기 일반식(Ⅲ)의 화합물의 암모늄 염 형태와, 나트륨시아노보로히드라이드의 존재하에 반응시킨 후, 임의로 염중에 고정된 화합물 또는 포함된 염을 유리 화합물로 전환시킴으로써 일반식(Ⅰ)의 화합물 및 이의 염을 제조하는 방법;The aldehyde of the following general formula (II) is reacted with the ammonium salt form of the compound of the general formula (III) in the presence of sodium cyanoborohydride, and then optionally the compound immobilized in the salt or the contained salt is converted into a free compound. A process for preparing the compound of formula (I) and salts thereof by conversion; [화학식 5][Formula 5] [화학식 6][Formula 6] NH(R1)R2 (Ⅲ)NH (R1) R2 (III) 상기 식중, A1, R1 및 R2는 제1항에 정의된 바와 같다.Wherein A 1, R 1 and R 2 are as defined in claim 1. 하나 또는 그 이상의 제1항의 화합물을 통상적인 약학적 보조 성분과 혼합된 상태로 포함하는 약물.A drug comprising one or more compounds of claim 1 in admixture with conventional pharmaceutical auxiliary ingredients. 심장 혈관 질환의 예방 및/또는 치료용 약물의 제조에 제1항의 화합물을 사용하는 방법.A method of using the compound of claim 1 in the manufacture of a medicament for the prophylaxis and / or treatment of cardiovascular disease. 안압 상승으로 인한 눈의 질환의 예방 및/또는 치료용 약물의 제조에 제1항의 화합물을 사용하는 방법.A method of using the compound of claim 1 in the manufacture of a medicament for the prevention and / or treatment of diseases of the eye due to elevated intraocular pressure. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019960703871A 1994-01-19 1995-01-18 Benzylamine Derivatives Including Nitrooxy Groups, And Their Uses For The Treatment Of Cardiovascular Diseases And Intraocular Pressure Elevation Withdrawn KR970700646A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH15794 1994-01-19
CH157/94-2 1994-01-19
PCT/EP1995/000167 WO1995019952A1 (en) 1994-01-19 1995-01-18 Nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure

Publications (1)

Publication Number Publication Date
KR970700646A true KR970700646A (en) 1997-02-12

Family

ID=4180558

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960703871A Withdrawn KR970700646A (en) 1994-01-19 1995-01-18 Benzylamine Derivatives Including Nitrooxy Groups, And Their Uses For The Treatment Of Cardiovascular Diseases And Intraocular Pressure Elevation

Country Status (8)

Country Link
EP (1) EP0740649A1 (en)
JP (1) JPH09507672A (en)
KR (1) KR970700646A (en)
CN (1) CN1143950A (en)
AU (1) AU679834B2 (en)
BR (1) BR9506549A (en)
CA (1) CA2181581A1 (en)
WO (1) WO1995019952A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
KR101224798B1 (en) * 2007-10-05 2013-01-21 어큐셀라 인코포레이티드 Alkoxy Compounds for Disease Treatment
WO2009058216A1 (en) 2007-11-01 2009-05-07 Acucela, Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
WO2011003103A2 (en) 2009-07-02 2011-01-06 Acucela, Inc. Pharmacology of visual cycle modulators
IN2012DN05028A (en) * 2009-12-07 2015-10-23 Univ Johns Hopkins
CN104703598A (en) 2012-01-20 2015-06-10 奥克塞拉有限公司 Substituted heterocyclic compounds for disease treatment
JP6405312B2 (en) * 2012-10-23 2018-10-17 ニコックス サイエンス アイルランド Quinone-based nitric oxide donor compounds for ophthalmology
RS58174B1 (en) * 2013-01-18 2019-03-29 Cardioxyl Pharmaceuticals Inc Pharmaceutical compositions comprising nitroxyl donors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56113748A (en) * 1980-02-13 1981-09-07 Kowa Co Aminoethanol derivative and its preparation
NL8802276A (en) * 1988-09-15 1990-04-02 Cedona Pharm Bv MEDICINAL PRODUCT WITH RELAXING EFFECT, CONTAINING A NITRATE ESTER AS ACTIVE SUBSTANCE.
NL9001955A (en) * 1990-09-05 1992-04-01 Cedona Pharm Bv NEW THIAZOLIDINE DERIVATIVES.

Also Published As

Publication number Publication date
AU679834B2 (en) 1997-07-10
AU1535095A (en) 1995-08-08
CA2181581A1 (en) 1995-07-20
WO1995019952A1 (en) 1995-07-27
MX9602847A (en) 1997-12-31
CN1143950A (en) 1997-02-26
EP0740649A1 (en) 1996-11-06
JPH09507672A (en) 1997-08-05
BR9506549A (en) 1997-10-14

Similar Documents

Publication Publication Date Title
KR920021523A (en) Novel urea derivatives, methods for their preparation and pharmaceutical compositions containing them
KR940005633A (en) Imidate derivatives of pharmaceutically useful anticonvulsant sulfamate
ATE117688T1 (en) HETEROCYCLIC AMINE WITH CNS ACTIVITY.
HU913603D0 (en) Method for producing n-substituted heterocyclic compounds and method for producing pharmaceutical preparatives containing said compounds as active substance
KR890005148A (en) N-acylamino acid derivatives and uses thereof
RU2002101935A (en) Amine and amide derivatives as ligands for the neuropeptide Y receptor Y5 used to treat obesity and other disorders
Domino et al. Pharmacological properties of Benzazoles I. Relationship between structure and paralyzing action
DE3681517D1 (en) THIAZOLIDE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF.
KR940006590A (en) Compounds useful for treating Alzheimer's disease and as hypoglycemic agents
DE69120100D1 (en) Annealed thiophene derivatives, their preparation and use
KR970700646A (en) Benzylamine Derivatives Including Nitrooxy Groups, And Their Uses For The Treatment Of Cardiovascular Diseases And Intraocular Pressure Elevation
KR870007160A (en) Novel dihydrobenzofuran- and chromman-carboxamide derivatives, methods for their preparation and use as neuroleptics
KR960010612A (en) 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amide derivatives
ATE74352T1 (en) DECAHYDROCHINOLINE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE, INTERMEDIATE PRODUCTS FOR THEIR MANUFACTURE, THEIR USE AS MEDICINAL PRODUCTS AND PREPARATIONS CONTAINING THEM.
KR890001957A (en) N-aminobutyl-N-phenylarylamide derivatives, their preparation and application in therapy
ATE102482T1 (en) USE OF 1,4-DISUBSTITUTED PIPERIDINYL COMPOUNDS IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF INSOMNIA.
UA41928C2 (en) OXAZOLIDINE DERIVATIVES, METHOD OF OBTAINING THEM, PHARMACEUTICAL COMPOSITION AND METHOD OF ITS OBTAINING, METHOD OF TREATMENT OF DISEASES
ES8603443A1 (en) Piperazine derivatives with anticholinergic and/or antihistaminic activity
KR937000438A (en) 3-indolyl thioacetate derivative
ATE31921T1 (en) AMIDINE, PROCESS FOR THEIR PRODUCTION AND THEIR APPLICATION IN THERAPY.
ES8203354A1 (en) 1,2,4-Triazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing them.
ES512574A0 (en) "CARBOXYLATE DERIVATIVES PREPARATION PROCEDURE".
DE3870096D1 (en) 2,4,6-TRIAMINOPYRIMIDINE N-3-OXIDE-UREA DERIVATIVES, THEIR PRODUCTION AND THEIR COSMETIC AND DERMOPHARMACEUTICAL USE.
PT92591A (en) A process for the preparation of acryloxypropanolamines with a beta-adrenergic blocking agent and pharmaceutical compositions containing them
HUT71512A (en) N-(3-chlorophenyl)-piperazine derivatives for producing alkyl-trazodon derivatives and process for producing them

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19960718

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid